Epacadostat联合帕博利珠单抗对比安慰剂联合帕博利珠单抗治疗不可切除或转移性黑色素瘤的III期随机双盲研究
ECHO-301/KEYNOTE-252研究为国际多中心III期随机双盲试验,纳入706例不可切除III/IV期黑色素瘤患者,比较Epacadostat联合帕博利珠单抗与安慰剂联合帕博利珠单抗的疗效。结果显示两组在无进展生存期和总生存期上均无显著差异,最常见≥3级治疗相关不良事件为脂肪酶升高。
要点
- Epacadostat联合帕博利珠单抗未改善PFS或OS,与安慰剂联合帕博利珠单抗无显著差异。
- IDO1抑制作为增强抗PD-1治疗策略的有效性仍不确定。
- 两组安全性相似,最常见≥3级治疗相关不良事件为脂肪酶升高。
核心结论
- Epacadostat 100 mg每日两次联合帕博利珠单抗对比安慰剂联合帕博利珠单抗,在不可切除或转移性黑色素瘤患者中未改善无进展生存期或总生存期。
- IDO1抑制作为增强抗PD-1治疗活性的策略在癌症中的 usefulness 仍不确定。
研究设计与样本
- 国际随机安慰剂对照双盲平行组III期试验,纳入706例不可切除III期或IV期黑色素瘤患者,随机1:1分配。
- 患者按PD-L1表达和BRAFV600突变状态分层,接受Epacadostat 100 mg口服每日两次联合帕博利珠单抗200 mg静脉每3周或安慰剂联合帕博利珠单抗,最长2年。
- 主要终点为意向治疗人群的无进展生存期和总生存期。
主要发现
- 最常见≥3级治疗相关不良事件为脂肪酶升高,Epacadostat联合组14例(4%)对比安慰剂联合组11例(3%)。
- 治疗相关严重不良事件:Epacadostat联合组37例(10%)对比安慰剂联合组32例(9%),两组均无治疗相关死亡。
临床怎么用
- 不推荐在不可切除或转移性黑色素瘤中使用Epacadostat 100 mg每日两次联合帕博利珠单抗。
- IDO1抑制联合抗PD-1治疗的策略需进一步探索,当前证据不支持常规临床应用。
局限性
- 研究在第二次中期分析后停止,随访仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma. In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab versus placebo plus pembrolizumab. METHODS: In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening. Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks or placebo plus pembrolizumab for up to 2 years. We used block randomisation with a block size of four in each stratum. Primary endpoints were progression-free survival and overall survival in the intention-to-treat population. The safety analysis population included randomly assigned patients who received at least one dose of study treatment. The study was stopped after the second interim analysis; follow-up for safety is ongoing. This study is registered with ClinicalTrials.gov, number NCT02752074. FINDINGS: Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352). Median follow-up was 12·4 months (IQR 10·3-14·5). No significant differences were found between the treatment groups for progression-free survival (median 4·7 months, 95% CI 2·9-6·8, for epacadostat plus pembrolizumab vs 4·9 months, 2·9-6·8, for placebo plus pembrolizumab; hazard ratio [HR] 1·00, 95% CI 0·83-1·21; one-sided p=0·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1·13, 0·86-1·49; one-sided p=0·81). The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab. Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab. There were no treatment-related deaths in either treatment group. INTERPRETATION: Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma. The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain. FUNDING: Incyte Corporation, in collaboration with Merck Sharp & Dohme.
引用
- Long GV, Dummer R, Hamid O, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019. PMID: 31221619. doi:10.1016/S1470-2045(19)30274-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。